Taiwan ImmunAdd’s Dr Pi-Hui Liang discusses her transition from academic research to entrepreneurship, driven by the critical shortage of commercially available vaccine adjuvants. With a proprietary saponin-based platform addressing supply chain constraints and toxicity limitations of existing adjuvants, ImmunAdd aims to democratise access to advanced immunological tools whilst developing its own…
See our Cookie Privacy Policy Here
